<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PP</journal-id><journal-title-group><journal-title>Pharmacology &amp; Pharmacy</journal-title></journal-title-group><issn pub-type="epub">2157-9423</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/pp.2014.55057</article-id><article-id pub-id-type="publisher-id">PP-45843</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>MEDICINE &amp; HEALTHCARE</subject><subject>CHEMISTRY &amp; MATERIALS SCIENCE</subject></subj-group></article-categories><title-group><article-title>Transdermal Delivery of Gabapentin: Effect of Cosolvent and Microemulsion on Permeation through the Rat Skin</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chika</surname><given-names>J. Mbah</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Charles</surname><given-names>O. Nnadi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of 
Nigeria, Nsukka, Nigeria</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>cjmbah123@yahoo.com(CJM)</email>;<email>chasnnadi@yahoo.com(CON)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>05</month><year>2014</year></pub-date><volume>05</volume><issue>05</issue><fpage>471</fpage><lpage>478</lpage><history><date date-type="received"><day>30</day>	<month>Jauary</month>	<year>2014</year></date><date date-type="rev-recd"><day>6</day>	<month>April</month>	<year>2014</year>	</date><date date-type="accepted"><day>29</day>	<month>April</month>	<year>2014</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
	


	The objective of
the present study was to examine the influence of cosolvent system and micro-emulsion
formulation on in-vitro skin permeation of gabapentin, furthermore,
to characterize the physicochemical properties of drug-loaded oil-in-water
(o/w) and water-in-oil (w/o) cremophor 40-based microemulsions in comparison to
the blank counterparts. The cosolvent system prepared by homogenous mixing is
composed of ethanol-water and propylene glycol-water mixture (90:10, 80:20, 70:30
v/v) respectively. The microemulsion consisted of coconut oil, water and
mixture of cremophor 40 (surfactant) and ethanol (cosurfactant) and was
prepared by aqueous phase titration method. Physicochemical properties of
microemulsions were determined using reported procedures. Transdermal flux for
gabapentin was studied in-vitro using
modified Franz diffusion cells. The physicochemical properties of drug-loaded
microemulsions and their blank counterparts were generally alike, however,
slight variation in pH and viscosity was observed probably due to the intrinsic
properties of the drug. The ethanol-water system (70:30 v/v) gave higher flux
for gabapentin when compared to propylene glycol-water system (70:30 v/v). The
w/o microemulsion formulations resulted in, higher flux for gabapentin when
compared to o/w formulations. FTIR spectra of the untreated stratum corneum,
when compared to cosolvent system and microemulsion treated stratum corneum,
suggest the mechanism of permeation to be disruption of lipid bilayers and
keratin denaturation of the stratum corneum. The results show that
incorporation of gabapentin into microemulsions did not change the
microemulsion type. The in vitro permeation data obtained from
experimental work suggest that the cosolvent system (ethanol-water 70:30 v/v)
and w/o microemulsion formulations respectively, can be successfully used as
potential vehicles in developing transdermal therapeutic systems for
gabapentin. 

 

	
</p></abstract><kwd-group><kwd>Transdermal Delivery</kwd><kwd> Cosolvent System</kwd><kwd> Microemulsion</kwd><kwd> Gabapentin</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>The in-vitro study on permeation of drug through the skin is very vital in the selection of candidates for the de- velopment of transdermal dosage forms. Investigations of this type are generally done by using a diffusion cell whose donor and receiver compartments are separated by a membrane. Such membranes could come from hu- man skin (cadaver or surgical reduction), mice, pigs, rabbits and rats [<xref ref-type="bibr" rid="scirp.45843-ref1">1</xref>] . However, the main barrier to drug permeation through any of these membranes is the stratum corneum (SC) that has been reported to differ in terms of lipid composition, water content and morphological characteristics (thickness, number of pores and fol- licles). To overcome this barrier to transdermal delivery, formulation scientists have investigated a number of techniques such as chemical enhancement [<xref ref-type="bibr" rid="scirp.45843-ref2">2</xref>] -[<xref ref-type="bibr" rid="scirp.45843-ref4">4</xref>] , microemulsions [<xref ref-type="bibr" rid="scirp.45843-ref5">5</xref>] -[<xref ref-type="bibr" rid="scirp.45843-ref8">8</xref>] , nanoemulsions [<xref ref-type="bibr" rid="scirp.45843-ref9">9</xref>] -[<xref ref-type="bibr" rid="scirp.45843-ref11">11</xref>] , cosolvent systems [<xref ref-type="bibr" rid="scirp.45843-ref12">12</xref>] -[<xref ref-type="bibr" rid="scirp.45843-ref14">14</xref>] , ethosomes [<xref ref-type="bibr" rid="scirp.45843-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.45843-ref16">16</xref>] and organic solvents [<xref ref-type="bibr" rid="scirp.45843-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.45843-ref18">18</xref>] . Gabapentin, 2-[1-(aminomethyl) cyclo- hexyl] acetic acid is an excitatory amino acid antagonist. Clinically, the drug is used orally for the treatment of postherpatic neuralgia and adjunctive therapy for partial seizures [<xref ref-type="bibr" rid="scirp.45843-ref19">19</xref>] . As gabapentin is not appreciably metabo- lized, has short plasma half-life and its bioavailability inversely related to the drug dose, gabapentin was consi- dered a potential drug candidate for percutaneous absorption. Therefore, the aim of this present study was to in- vestigate the effect of cosolvent system and microemulsion formulation on the permeation of gabapentin in or- der to select a potential solvent system towards developing a transdermal therapeutic system.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Materials</title><p>Gabapentin (Pfizer, China), cremophor RH 40 (BASF, Germany), purified coconut oil (Nigeria), ethanol (Sigma and Aldrich, USA). All other chemicals and reagents were of analytical or high-performance liquid chromato- graphy (HPLC) grade, purchased from Sigma and Aldrich (USA).</p></sec><sec id="s2_2"><title>2.2. Cosolvent System Preparation</title><p>Ethanol and water or propylene glycol and water were homogenously mixed in different ratios to obtain binary solvent systems of 90:10, 80:20 and 70:30 v/v respectively.</p></sec><sec id="s2_3"><title>2.3. Microemulsion Preparation</title><p>A pseudoternary phase diagram was constructed by using the aqueous phase titration method [<xref ref-type="bibr" rid="scirp.45843-ref20">20</xref>] . Two opti- mized formulations were selected at surfactant:cosurfactant ratio of 1:1 and 1:2 respectively, that were likely to produce both o/w and w/o microemulsions. The w/o and o/w microemulsion formulations were designated as ME<sub>a</sub> and ME<sub>b</sub> respectively, for 1:1 surfactant:cosurfactant mixture ratio; ME<sub>c</sub> and ME<sub>d</sub> respectively, for 1:2 sur- factant:cosurfactant mixture ratio. Optimization of microemulsion was in terms of droplet size and polydispersi- ty index. Gabapentin was incorporated at a concentration of 5% w/w to the microemulsion formulations by com- bining appropriate amounts of each component and mixed by vigorously stirring for 5 minutes. The samples were characterized and compared to their blank counterparts.</p></sec><sec id="s2_4"><title>2.4. pH Measurement</title><p>The apparent pH of the formulations was measured in triplicate at 25˚C using a pH meter with combination electrode (Eutech, Japan).</p></sec><sec id="s2_5"><title>2.5. Droplet Size Analysis</title><p>The determination was carried out using photomicrograph (Moticam, Japan). The test was performed on a fil- tered microemulsion sample that was placed on a slide after being diluted with distilled water. The filtration was done through 0.22 mm membrane filter. Polydispersity index was estimated from the ratio of standard deviation to the mean droplet size.</p></sec><sec id="s2_6"><title>2.6. Viscosity Measurement</title><p>Viscosity of the samples was measured at 25˚C using, a cone and plate viscometer (UTV Gallenkamp, England). A sample volume of 5 ml was used for the viscosity measurement and the test was carried out in triplicate.</p></sec><sec id="s2_7"><title>2.7. Surface Tension Measurement</title><p>Surface tension of the samples was measured at 25˚C using Du No&#252;y tensiometer. A sample volume of 5 ml was placed on the tensiometer plate and the force required pulling a circular ring out of the sample recorded. The test was performed in triplicate.</p></sec><sec id="s2_8"><title>2.8. Stability Measurement</title><p>Stability of the samples was studied by allowing the microemulsions to stand on the laboratory shelf for 21 days while observing them for phase separation and/or creaming.</p></sec><sec id="s2_9"><title>2.9. Preparation of Rat Abdominal Skin</title><p>The approval to carry out the animal studies was obtained from Faculty of Veterinary Medicine, University of Nigeria, Nsukka animal ethics committee. Male Wister rats were sacrificed with prolonged exposure to chloro- form. Hairs on the skin of animal were removed with electrical clipper. Full thickness skin was surgically re- moved from each rat. The epidermis was prepared from the full thickness skin by heat separation technique [<xref ref-type="bibr" rid="scirp.45843-ref21">21</xref>] that involved soaking entire abdominal skin in water at 60˚C for 1 minute. The epidermis was cut into 4.5 &#215; 4.5 cm<sup>2</sup> pieces and used for the permeation study. The unused epidermis was wrapped with aluminum foil and stored at −20˚C until needed. Prior to being used, the stored epidermis was allowed to thaw, cut into 4.5 &#215; 4.5 cm<sup>2</sup> pieces and hydrated by placing in phosphate buffer saline (PBS) overnight before use [<xref ref-type="bibr" rid="scirp.45843-ref22">22</xref>] .</p></sec><sec id="s2_10"><title>2.10. In-Vitro Skin Permeability Studies</title><p>The studies were done using modified Franz diffusion cells. The diffusional area of the cells was 2.54 cm<sup>2</sup>. The diffusion cells were connected with a circulating water bath and the temperature was controlled at 37˚C. Phos- phate buffer saline (PBS) used as a receiver fluid was placed in the receiver compartment that has a volume of 25 ml and was stirred by an externally driven Teflon-coated magnetic bar. The prepared epidermis was sand- wiched between the receiver compartment and the donor compartment with the stratum corneum facing upwards. The donor compartment was clamped. One ml of cosolvent system containing 5 mg of gabapentin or drug- loaded microemulsion was applied onto skin surface facing the donor compartment that was covered with a glass lid. The sampling arm of the donor compartment was also covered with aluminum foil. At suitable time interval (0, 1, 2, 4, 6, 8, 10, 12 and 24 h), 1 ml of each sample was withdrawn from the center of the receiver compartment with a syringe connected with a needle. An equal volume of fresh PBS (37˚C) was replenished immediately. The amount of drug in the receiver fluid was determined spectrophotometrically at 210 nm.</p></sec><sec id="s2_11"><title>2.11. Spectrophotometric Assay</title><p>The concentrations of gabapentin permeated to the receiver fluids were quantitatively determined by UV/VIS spectrophotometer (Jeenway 6405, England). The samples were analyzed at maximum wavelength of 210 nm. The calibration curve (absorbance versus drug concentration) was constructed by measuring standard solutions of the drug in PBS in the concentration range of 5 - 50 &#181;g/ml. Validation of the method was performed to ensure that the calibration curve was in the linearity range of the assay and the coefficients of variation were less than 2% both intra-day and inter-day.</p></sec><sec id="s2_12"><title>2.12. Data Analysis</title><p>The skin permeation data were measured as the cumulative drug permeation per unit of skin surface Q<sub>t</sub>/S (S = 2.54 cm<sup>2</sup>). The cumulative drug permeation (Q<sub>t</sub>) was calculated from equation (1):</p><disp-formula id="scirp.45843-formula62"><label>(1)</label><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\3-2500418x\4bd40b63-fe9e-4011-b074-c1737410cbf6.png"/></disp-formula><p>where, C<sub>t</sub> is the drug concentration of the receiver fluid at each sampling time, C<sub>i</sub> is the drug concentration of the i<sup>th</sup> sample, V<sub>r</sub> and V<sub>s</sub> are the volumes of the receiver fluid and sample respectively. The steady-state fluxes (J<sub>ss(6-24 h)</sub>) were determined as the slope of the linear portion of the plots obtained by graphing cumulative drug permeation per unit of skin surface versus time. One-way analysis of variance (ANOVA) was used to compare fluxes of different vehicles and a p-value of 0.05 was considered to be statistically significant. The penetration enhancing effect of each vehicle was calculated in terms of enhancement ratio (ER) using Equation (2):</p><disp-formula id="scirp.45843-formula63"><label>(2)</label><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\3-2500418x\bfc121ba-ce57-444d-89d4-845d7085b123.png"/></disp-formula></sec><sec id="s2_13"><title>2.13. Preparation of Stratum Corneum (SC) for Biophysical Analysis</title><p>The rat stratum corneum samples were prepared by soaking freshly prepared epidermis membrane in a 0.1 % trypsin solution for 12 h. The SC samples were cleaned by washing with distilled water and blotted dry and used in the FTIR [<xref ref-type="bibr" rid="scirp.45843-ref23">23</xref>] studies.</p></sec><sec id="s2_14"><title>2.14. Fourier Transform Infrared (FTIR) Analysis</title><p>The analysis was performed on both untreated and treated rat stratum corneum. The vehicle-treated and un- treated (control) SC samples respectively were vacuum-dried at 25˚C &#177; 1˚C for 48 h and stored in desiccators to remove traces of solvent. The control samples were treated in phosphate buffer saline (PBS). All samples were treated in the respective vehicles for 24 h prior to been vacuum-dried. The completely dried samples were stu- died by FTIR (Shimadzu 8400S, Japan). Peaks occurring near 2850 cm<sup>−1</sup> and 2920 cm<sup>−1</sup> that were due to sym- metric and asymmetric C-H stretching vibrations respectively as well as those at 1550 cm<sup>−1</sup> and 1650 cm<sup>−1</sup> indi- cating amides (C=O) stretching vibrations were characterized.</p></sec></sec><sec id="s3"><title>3. Results and Discussion</title><p>Transdermal delivery of drugs depends on their permeability through SC that in turn depends on the de- velopment of optimal vehicles. This route of drug delivery is important for drugs of high potency and helps to avoid problems with gastrointestinal intolerance and short half-life, reduces first-pass liver metabolism and eliminates the need for intravenous administration. Our study chose cosolvent system and microemulsion as vehicles to investigate the transdermal delivery of gabapentin. Cosolvent system and microemulsion are amongst the most useful and interesting drug delivery systems [<xref ref-type="bibr" rid="scirp.45843-ref24">24</xref>] -[<xref ref-type="bibr" rid="scirp.45843-ref26">26</xref>] . One of the plots obtained from microemulsion formulations using 20% w/w mixture of surfactant:cosurfactant ratios is shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. In the figure, the enclosed area marks the microemulsion region. From the microemulsion region, two repre- sentative microemulsion formulations referred to as w/o and o/w respectively, were identified and designated as ME<sub>a</sub> (w/o) and ME<sub>b</sub> (o/w) for surfactant:cosurfactant in the ratio of 1:1; ME<sub>c</sub> (w/o) and ME<sub>d</sub> (o/w) for surfactant:cosurfactant in the ratio of 1:2 respectively. From the study, it was observed that the microemulsion areas of the pseudoternary phase diagrams were large indicating the efficiency of ethanol as a cosurfactant in increasing the flexibility of the interfacial film. All the drug-loaded cremophor 40-based microemulsions and their blank counterparts were clear yellowish liquids. As shown in <xref ref-type="table" rid="table1">Table 1</xref>, the results of the physicochemical properties of gabapentin-loaded microemulsions compared to the blank counterparts indicated that the types of cremophor 40-based microemulsions were not altered after 5% w/w of the drug was incorporated. However, slight changes in pH and viscosity observed could be due to the intrinsic properties of the drug. All the droplets were found in the microemulsion range which indicated the suitability of formulation for transdermal drug delivery. The stability study, showed the formulations to be very stable. The skin permeation profile of gabapen- tin from rat skin is represented in <xref ref-type="fig" rid="fig2">Figure 2</xref>. The extent of skin permeation of gabapentin in all the vehicles de- pended on the time of monitoring (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The drug showed 3479.94, 3353.39, and 911.33 &#181;g/mL in opti- mized w/o micro emulsion, ethanol (90:10) and propylene glycol (70:30) respectively compared with the 166.31 &#181;g/mL of the control after 24 h which are higher than 187.83, 198.36, 8.19 and 6.78 &#181;g/mL in optimized w/o microemulsion, ethanol (90:10), propylene glycol (70:30) and control respectively after 1 h. The lag period for permeation of gabapentin through rat epidermis from all vehicles was found to be about 1 h. The fluxes and</p><fig id="fig1"><label>Figure 1</label><caption><p> Pseudoternary phase diagram of coconut oil/water/ cremophor 40 RH:ethanol (1:2) microemulsion formulation</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\3-2500418x\7c386e96-b19b-411a-8f8d-0606a96ada16.png"/></fig><disp-formula id="scirp.45843-formula64"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\3-2500418x\9bf95ccf-9eed-4f14-9827-92d5af5a7491.png"/></disp-formula><p>&#180;----&#180; ME<sub>a</sub>; ▲-----▲ Ethanol-Water 70:30</p><p>■----■ ME<sub>c</sub>; &#183;----&#183; Water</p><p><xref ref-type="fig" rid="fig2">Figure 2</xref>. Permeation profile of gaba- pentin in various vehicles.</p><table-wrap id="table1"  position="float"><object-id pub-id-type="pii">Table 1</object-id><label>Table 1</label><caption><p>. Physicochemical characteristics of the microemulsions</p></caption><table><thead><tr><th align="center" valign="middle" >Formulation</th><th align="center" valign="middle" >pH</th><th align="center" valign="middle" >Droplet size (nm)</th><th align="center" valign="middle" >Polydispersity index (PDI)</th><th align="center" valign="middle" >Surface tension</th><th align="center" valign="middle" >Viscosity</th></tr></thead><tbody><tr><td align="center" valign="middle" >Blank<sup>*</sup></td><td align="center" valign="middle" >7.54 &#177; 0.52</td><td align="center" valign="middle" >85.7 &#177;0.1</td><td align="center" valign="middle" >0.0098</td><td align="center" valign="middle" >83.6 &#177; 1.2</td><td align="center" valign="middle" >150 &#177; 17</td></tr><tr><td align="center" valign="middle" >ME<sub>a</sub></td><td align="center" valign="middle" >7.62 &#177; 0.14</td><td align="center" valign="middle" >85.8 &#177; 0.2</td><td align="center" valign="middle" >0.0098</td><td align="center" valign="middle" >84.4 &#177; 1.2</td><td align="center" valign="middle" >151 &#177; 20</td></tr><tr><td align="center" valign="middle" >Blank</td><td align="center" valign="middle" >7.43 &#177; 0.21</td><td align="center" valign="middle" >89.8 &#177; 0.6</td><td align="center" valign="middle" >0.0096</td><td align="center" valign="middle" >85.2 &#177; 1.1</td><td align="center" valign="middle" >145 &#177; 14</td></tr><tr><td align="center" valign="middle" >ME<sub>b</sub></td><td align="center" valign="middle" >7.21 &#177; 0.33</td><td align="center" valign="middle" >89.9 &#177; 0.3</td><td align="center" valign="middle" >0.0097</td><td align="center" valign="middle" >86.4 &#177; 1.1</td><td align="center" valign="middle" >148 &#177; 12</td></tr><tr><td align="center" valign="middle" >Blank</td><td align="center" valign="middle" >7.33 &#177; 0.62</td><td align="center" valign="middle" >93.7 &#177; 0.1</td><td align="center" valign="middle" >0.0100</td><td align="center" valign="middle" >84.3 &#177; 0.9</td><td align="center" valign="middle" >151 &#177; 20</td></tr><tr><td align="center" valign="middle" >ME<sub>c</sub></td><td align="center" valign="middle" >7.52 &#177; 0.41</td><td align="center" valign="middle" >93.7 &#177; 0.1</td><td align="center" valign="middle" >0.0100</td><td align="center" valign="middle" >85.0 &#177; 0.9</td><td align="center" valign="middle" >154 &#177; 15</td></tr><tr><td align="center" valign="middle" >Blank</td><td align="center" valign="middle" >7.34 &#177; 0.22</td><td align="center" valign="middle" >95.2 &#177; 0.5</td><td align="center" valign="middle" >0.0095</td><td align="center" valign="middle" >84.2 &#177; 0.4</td><td align="center" valign="middle" >153 &#177; 17</td></tr><tr><td align="center" valign="middle" >ME<sub>d</sub></td><td align="center" valign="middle" >7.52 &#177; 0.73</td><td align="center" valign="middle" >95.2 &#177; 0.5</td><td align="center" valign="middle" >0.0095</td><td align="center" valign="middle" >84.3 &#177; 0.6</td><td align="center" valign="middle" >154 &#177; 17</td></tr></tbody></table></table-wrap><p><sup>*</sup>The apparent similarities in the physicochemical properties of the blank and drug-loaded microemulsions (<xref ref-type="table" rid="table2">Table 2</xref>) indicated that the bulk components (water, oil and surfactant/co-surfactant) of the microemulsion, which con- trol the physicochemical properties of microemulsion have fairly equal effects on the permeation of gabapentin through the excised rat skin; and that the permeation performance of gabapentin in this study is strictly controlled by the nature (w/o or o/w) of the microemulsion.</p><p>permeability coefficients of gabapentin from cosolvent systems and microemulsion formulations are shown in <xref ref-type="table" rid="table2">Table 2</xref>. It was further demonstrated that the skin permeation rate of gabapentin from the binary ethanol-water (70:30 v/v) system was higher than that from propylene glycol-water (70:30 v/v) system. However, for ethanol- water systems, the permeability flux for gabapentin in the ratio of 90:10 v/v, 80:20 v/v and 70:30 v/v was found to be 8.434 &#177; 0.176 &#181;g∙cm<sup>−</sup><sup>2</sup>∙h<sup>−</sup><sup>1</sup>, 14.774 &#177; 0.409 &#181;g∙cm<sup>−</sup><sup>2</sup>∙h<sup>−</sup><sup>1</sup>, and 63.290 &#177; 1.62 &#181;g∙cm<sup>−</sup><sup>2</sup>∙h<sup>−</sup><sup>1</sup> respectively. This may be due to differences in their influence on the biophysical properties of the stratum corneum. With the microemulsion formulations, it was found that the flux for gabapentin from ME<sub>a</sub> (128.215 &#177; 1.84 &#181;g∙cm<sup>−</sup><sup>2</sup>∙h<sup>−</sup><sup>1</sup>) and ME<sub>c</sub> (61.137 &#177; 0.896 &#181;g∙cm<sup>−</sup><sup>2</sup>∙h<sup>−</sup><sup>1</sup>) were higher than those of ME<sub>b</sub> (5.542 &#177; 0.587 &#181;g∙cm<sup>−</sup><sup>2</sup>∙h<sup>−</sup><sup>1</sup>) and ME<sub>d</sub> (4.728 &#177; 0.220 &#181;g∙cm<sup>−</sup><sup>2</sup>∙h<sup>−</sup><sup>1</sup>) respectively. The ethanol-water system 70:30 v/v and microemulsion formulations (ME<sub>a</sub> and ME<sub>c</sub>) respectively, provided good permeability and the required flux through the skin for the drug. The results of the FTIR analysis are shown in <xref ref-type="table" rid="table3">Table 3</xref>. The absorbance values were calculated from the vibra- tion frequency intensities. The untreated SC (control) showed peaks that are due to molecular vibrations of lipids and proteins present in the SC. The absorption bands at 2927 cm<sup>−</sup><sup>1</sup> and 2860 cm<sup>−</sup><sup>1</sup> could be attributed to the asymmetric (-CH<sub>2</sub>) and symmetric (-CH<sub>2</sub>) vibrations of long chain hydrocarbons of lipids respectively. The two bands at 1637cm<sup>−</sup><sup>1</sup> and 1580 cm<sup>−</sup><sup>1</sup> were due to the amide I (C=O stretching vibration), and amide II (C-N bend- ing vibration) respectively, of the SC proteins. With the vehicle treated SC, significant decrease in peak height for asymmetric and symmetric C-H stretching vibrations was observed. The same observation was made for amide I, and amide II stretching vibrations. The peak positions were however, not altered in both treated and untreated SC. The significant decrease in peak height with 70:30 v/v ethanol-water suggests partial extraction of the lipids from the SC. Extraction of the lipids from the SC has been reported [<xref ref-type="bibr" rid="scirp.45843-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.45843-ref28">28</xref>] to enhance percutaneous absorption of drugs. Likewise, the significant decrease in peak height with microemulsion type (ME<sub>a</sub>), suggests disruption of lipid bilayer and keratin denaturation by hydration. Hydration increases permeation flux for both polar and nonpolar permeants by increasing lipid fluidity in the bilayer region; competing for hydrogen-bonding site and lessening restrictions on protein rearrangements [<xref ref-type="bibr" rid="scirp.45843-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.45843-ref30">30</xref>] . The increase in permeability of gabapentin observed in this study may be due to increase in, drug diffusivity through the hydrated SC. Previous reports have shown that w/o emulsions enhanced transdermal delivery by hydration of the skin epidermis [<xref ref-type="bibr" rid="scirp.45843-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.45843-ref32">32</xref>] .</p><table-wrap id="table2"  position="float"><object-id pub-id-type="pii">Table 2</object-id><label>Table 2</label><caption><p>. Skin permeation parameters of gabapentin through stratum corneum from various vehicles</p></caption><table><thead><tr><th align="center" valign="middle" >Vehicles</th><th align="center" valign="middle" >J<sub>ss</sub> (&#181;g∙cm<sup>−2</sup>∙h<sup>−1</sup>)</th><th align="center" valign="middle" >K<sub>p</sub> &#215; 10<sup>3</sup> (cm∙h<sup>−1</sup>)</th><th align="center" valign="middle" >ER</th></tr></thead><tbody><tr><td align="center" valign="middle" >Control</td><td align="center" valign="middle" >3.569 &#177; 0.058</td><td align="center" valign="middle" >0.7138 &#177; 0.007</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >10% ethanol</td><td align="center" valign="middle" >8.434 &#177; 0.176</td><td align="center" valign="middle" >1.687 &#177; 0.080</td><td align="center" valign="middle" >2.4</td></tr><tr><td align="center" valign="middle" >20% ethanol</td><td align="center" valign="middle" >14.774 &#177; 0.409</td><td align="center" valign="middle" >2.955 &#177; 0.038</td><td align="center" valign="middle" >4.1</td></tr><tr><td align="center" valign="middle" >30% ethanol</td><td align="center" valign="middle" >63.290 &#177; 1.62</td><td align="center" valign="middle" >12.658 &#177; 0.293</td><td align="center" valign="middle" >17.7</td></tr><tr><td align="center" valign="middle" >10% Pg</td><td align="center" valign="middle" >15.984 &#177; 0.988</td><td align="center" valign="middle" >3.197 &#177; 0.123</td><td align="center" valign="middle" >4.5</td></tr><tr><td align="center" valign="middle" >20% Pg</td><td align="center" valign="middle" >15.761 &#177; 0.468</td><td align="center" valign="middle" >3.152 &#177; 0.074</td><td align="center" valign="middle" >4.4</td></tr><tr><td align="center" valign="middle" >30% Pg</td><td align="center" valign="middle" >12.263 &#177; 0.657</td><td align="center" valign="middle" >2.453 &#177; 0.051</td><td align="center" valign="middle" >3.4</td></tr><tr><td align="center" valign="middle" >ME<sub>a</sub></td><td align="center" valign="middle" >128.215 &#177; 1.84</td><td align="center" valign="middle" >25.643 &#177; 0.325</td><td align="center" valign="middle" >35.9</td></tr><tr><td align="center" valign="middle" >ME<sub>b</sub></td><td align="center" valign="middle" >5.542 &#177; 0.587</td><td align="center" valign="middle" >1.108 &#177; 0.047</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >ME<sub>c</sub></td><td align="center" valign="middle" >61.137 &#177; 0.896</td><td align="center" valign="middle" >12.227 &#177; 0.134</td><td align="center" valign="middle" >17.1</td></tr><tr><td align="center" valign="middle" >ME<sub>d</sub></td><td align="center" valign="middle" >4.728 &#177; 0.220</td><td align="center" valign="middle" >0.9456 &#177; 0.029 </td><td align="center" valign="middle" >1.3</td></tr></tbody></table></table-wrap><p>ME<sub>a</sub><sub>-</sub><sub>d</sub> = microemulsion codes, J<sub>ss</sub> = steady-state flux, K<sub>p</sub> = permeability coefficient, ER = enhancement ratio, Pg = propylene glycol</p><table-wrap id="table3"  position="float"><object-id pub-id-type="pii">Table 3</object-id><label>Table 3</label><caption><p>. Peak height of asymmetric, symmetric C-H stretching and amide absorbance of rat stratum corneum</p></caption><table><thead><tr><th align="center" valign="middle" >Vehicle</th><th align="center" valign="middle"  colspan="2"  >Asymmetric C-H  stretching</th><th align="center" valign="middle"  colspan="2"  >Symmetric C-H  stretching</th><th align="center" valign="middle"  colspan="2"  >Amide I stretching  vibration</th><th align="center" valign="middle"  colspan="2"  >Amide II bending  vibration</th></tr></thead><tbody><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Peak height</td><td align="center" valign="middle" >% decrease in peak height</td><td align="center" valign="middle" >Peak height</td><td align="center" valign="middle" >% decrease in peak height</td><td align="center" valign="middle" >Peak height</td><td align="center" valign="middle" >% decrease in peak height</td><td align="center" valign="middle" >Peak height</td><td align="center" valign="middle" >% decrease in peak height</td></tr><tr><td align="center" valign="middle" >Untreated</td><td align="center" valign="middle" >0.4149</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.5223</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.5403</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.4255</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Ethanol-water 70:30 v/v</td><td align="center" valign="middle" >0.2943</td><td align="center" valign="middle" >29.07</td><td align="center" valign="middle" >0.3898</td><td align="center" valign="middle" >25.37</td><td align="center" valign="middle" >0.2546</td><td align="center" valign="middle" >52.88</td><td align="center" valign="middle" >0.2214</td><td align="center" valign="middle" >47.97</td></tr><tr><td align="center" valign="middle" >Mea</td><td align="center" valign="middle" >0.1381</td><td align="center" valign="middle" >66.71</td><td align="center" valign="middle" >0.1824</td><td align="center" valign="middle" >65.08</td><td align="center" valign="middle" >0.1245</td><td align="center" valign="middle" >76.96</td><td align="center" valign="middle" >0.1231</td><td align="center" valign="middle" >71.07</td></tr></tbody></table></table-wrap></sec><sec id="s4"><title>4. Conclusion</title><p>Both cosolvent system (ethanol-water, 70:30 v/v) and w/o microemulsion formulations (ME<sub>a</sub> and ME<sub>c</sub>) very significantly enhanced the skin permeation of gabapentin through the excised rat skin. Results of the study therefore suggest that microemulsion type (w/o) and cosolvent system (ethanol-water, 70:30 v/v) can be suc- cessfully used as vehicles to enhance skin permeation of gabapentin.</p></sec></body><back><ref-list><title>References</title><ref id="scirp.45843-ref1"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>PRIBOSKY</surname><given-names> J.</given-names></name>,<name name-style="western"><surname> TAKAYAMAK</surname><given-names> K.</given-names></name>,<name name-style="western"><surname> NAGAI</surname><given-names> T.</given-names></name>,<name name-style="western"><surname> WAITZOVA</surname><given-names> D. </given-names></name>,<name name-style="western"><surname> ELIS</surname><given-names> J. </given-names></name>,<etal>et al</etal>. (1987)<article-title>PRIBOSKY, J., TAKAYAMAK, K., NAGAI, T., WAITZOVA, D. AND ELIS, J.  EVALUATION OF IN-VITRO AND IN-SITU TRANSDERMAL ABSORPTION OF DRUGS IN PIG AND RAT SKIN</article-title><source>. CHEMICAL AND PHARMACEUTICAL BULLETIN (TOKYO)</source><volume> 35</volume>,<fpage> 4915</fpage>-<lpage>4920</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.45843-ref2"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>YAMANE</surname><given-names> M.A.</given-names></name>,<name name-style="western"><surname> WILLIAMS</surname><given-names> A.C. </given-names></name>,<name name-style="western"><surname> BARRY</surname><given-names> B.W. </given-names></name>,<etal>et al</etal>. (<year>1995</year>)<article-title>TERPENES PENETRATION ENHANCERS IN PROPYLENE GLYCOL/WATER COSOLVENT SYSTEMS: EFFECTIVENESS AND MECHANISMS OF ACTIONS</article-title><source>. JOURNAL OF PHARMACY AND PHARMACOLOGY</source><volume> 47</volume>,<fpage> 978</fpage>-<lpage>989</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1111/J.2042-7158.1995.TB03282.X</pub-id></mixed-citation></ref><ref id="scirp.45843-ref3"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>STOTT</surname><given-names> P.W.</given-names></name>,<name name-style="western"><surname> WILLIAMS</surname><given-names> A.C. </given-names></name>,<name name-style="western"><surname> BARRY</surname><given-names> B.W. </given-names></name>,<etal>et al</etal>. (<year>2001</year>)<article-title>MECHANISSTIC STUDY INTO THE ENHANCED TRANSDERMAL PERMEATION OF A MODEL Β-BLOCKER, PROPRANOLOL, BY FATTY ACIDS: A MELTING POINT DEPRESSION EFFECT</article-title><source>. INTERNATIONAL JOURNAL OF PHARMACEUTICS</source><volume> 219</volume>,<fpage> 161</fpage>-<lpage>176</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/S0378-5173(01)00645-7</pub-id></mixed-citation></ref><ref id="scirp.45843-ref4"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>NARISHETTY</surname><given-names> S.T.K. </given-names></name>,<name name-style="western"><surname> PANCHAGNULA</surname><given-names> R. </given-names></name>,<etal>et al</etal>. (<year>2004</year>)<article-title>TRANSDERMAL DELIVERY OF ZIDOVUDINE: EFFECTS OF TERPENES AND THEIR MECHANISM OF ACTION</article-title><source>. JOURNAL OF CONTROLLED RELEASE</source><volume> 95</volume>,<fpage> 367</fpage>-<lpage>379</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/J.JCONREL.2003.11.022</pub-id></mixed-citation></ref><ref id="scirp.45843-ref5"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>LEE</surname><given-names> P.J.</given-names></name>,<name name-style="western"><surname> LENGER</surname><given-names> R. </given-names></name>,<name name-style="western"><surname> SHESTRI</surname><given-names> V.P. </given-names></name>,<etal>et al</etal>. (<year>2003</year>)<article-title>NOVEL MICROEMULSION ENHANCER FORMULATION FOR SIMULTANEOUS TRANSDERMAL DELIVERY OF HYDROPHILIC AND HYDROPHOBIC DRUGS</article-title><source>. PHARMACEUTICAL RESEARCH</source><volume> 20</volume>,<fpage> 264</fpage>-<lpage>269</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1023/A:1022283423116</pub-id></mixed-citation></ref><ref id="scirp.45843-ref6"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>CHEN</surname><given-names> H.</given-names></name>,<name name-style="western"><surname> CHANG</surname><given-names> X.</given-names></name>,<name name-style="western"><surname> WENG</surname><given-names> T.</given-names></name>,<name name-style="western"><surname> ZHAO</surname><given-names> X.</given-names></name>,<name name-style="western"><surname> SAO</surname><given-names> H. YANG</given-names></name>,<name name-style="western"><surname> Y.</surname><given-names> XU</given-names></name>,<name name-style="western"><surname> H. </surname><given-names> YANG</given-names></name>,<name name-style="western"><surname> X. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2004</year>)<article-title>A STUDY OF MICROEMULSION SYSTEMS FOR TRANSDERMAL DELIVERY OF TRIPTOLIDE</article-title><source>. JOURNAL OF CONTROLLED RELEASE</source><volume> 98</volume>,<fpage> 427</fpage>-<lpage>436</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/J.JCONREL.2004.06.001</pub-id></mixed-citation></ref><ref id="scirp.45843-ref7"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>YUAN</surname><given-names> Y.</given-names></name>,<name name-style="western"><surname> LI</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> MO</surname><given-names> F. </given-names></name>,<name name-style="western"><surname> ZHONG</surname><given-names> D. </given-names></name>,<etal>et al</etal>. (<year>2006</year>)<article-title>INVESTIGATION OF MICROEMULSION SYSTEM FOR TRANSDERMAL DELIVERY OF MELOXICAM</article-title><source>. INTERNATIONAL JOURNAL OF PHARMACEUTICS</source><volume> 321</volume>,<fpage> 117</fpage>-<lpage>123</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/J.IJPHARM.2006.06.021</pub-id></mixed-citation></ref><ref id="scirp.45843-ref8"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SINTOV</surname><given-names> A.C. </given-names></name>,<name name-style="western"><surname> BOTNER</surname><given-names> S. </given-names></name>,<etal>et al</etal>. (<year>2006</year>)<article-title>TRANSDERMAL DRUG DELIVERY USING MICROEMULSION AND AQUEOUS SYSTEMS: INFLUENCE OF SKIN STORAGE CONDITIONS ON THE IN VITRO PERMEABILITY OF DICLOFENAC FROM AQUEOUS VEHICLE SYSTEMS</article-title><source>. INTERNATIONAL JOURNAL OF PHARMACEUTICS</source><volume> 311</volume>,<fpage> 55</fpage>-<lpage>62</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/J.IJPHARM.2005.12.019</pub-id></mixed-citation></ref><ref id="scirp.45843-ref9"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>BABOOTA</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> SHAKEEL</surname><given-names> F.</given-names></name>,<name name-style="western"><surname> AHUJA</surname><given-names> A.</given-names></name>,<name name-style="western"><surname> ALI</surname><given-names> J. </given-names></name>,<name name-style="western"><surname> SHAFIQ</surname><given-names> S. </given-names></name>,<etal>et al</etal>. (2007)<article-title>BABOOTA, S., SHAKEEL, F., AHUJA, A., ALI, J. AND SHAFIQ, S.  DESIGN DEVELOPMENT AND EVALUATION OF NOVEL NANOEMULSION FORMULATION FOR TRANSDERMAL POTENTIAL OF CELECOXIB</article-title><source>. ACTA PHARMACEUTICA</source><volume> 8</volume>,<fpage> 316</fpage>-<lpage>332</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.45843-ref10"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SHAFIQ</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> SHAKEEL</surname><given-names> F.</given-names></name>,<name name-style="western"><surname> TALEGAONKAR</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> AHMED</surname><given-names> F.J.</given-names></name>,<name name-style="western"><surname> KHAR</surname><given-names> R.K. </given-names></name>,<name name-style="western"><surname> ALI</surname><given-names> M. </given-names></name>,<etal>et al</etal>. (<year>2007</year>)<article-title>DEVELOPMENT AND BIOAVAILABILITY ASSESSEMENT OF RAMIPRIL NANOEMULSION FORMULATION</article-title><source>. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS</source><volume> 66</volume>,<fpage> 227</fpage>-<lpage>242</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/J.EJPB.2006.10.014</pub-id></mixed-citation></ref><ref id="scirp.45843-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">SHAKEEL, F., BABOOTA, S., AHUJA, A., ALI, J., AQUI, I.M. AND SHAFIQ, S. (2007) NANOEMULSIONS AS VEHICLES FOR TRANSDERMAL DELIVERY OF ACECLOFENAC. AAPS PHARMSCITECH, 8, E104. HTTP://DX.DOI.ORG/10.1208/PT0804104</mixed-citation></ref><ref id="scirp.45843-ref12"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>BEMER</surname><given-names> B.</given-names></name>,<name name-style="western"><surname> OTTE</surname><given-names> J.H.</given-names></name>,<name name-style="western"><surname> MAZZENGA</surname><given-names> G.C.</given-names></name>,<name name-style="western"><surname> STEFFENS</surname><given-names> R.J. </given-names></name>,<name name-style="western"><surname> EBERT</surname><given-names> C.D. </given-names></name>,<etal>et al</etal>. (<year>1989</year>)<article-title>ETHANOL:WATER MUTUALLY ENHANCED TRANSDERMAL THERAPEUTIC SYSTEM I: NITROGLYCERIN SOLUTION PROPERTIES AND MEMBRANE TRANSPORT</article-title><source>. JOURNAL OF PHARMACEUTICAL SCIENCES</source><volume> 78</volume>,<fpage> 314</fpage>-<lpage>318</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1002/JPS.2600780411</pub-id></mixed-citation></ref><ref id="scirp.45843-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">KURIHARA-BERGSTROM, T., KNUTSON, K., DENOBLE, L.J. AND GOATES, C.Y. (1990) PERCUTANEOUS ABSORPTION ENHANCEMENT OF AN IONIC MOLECULES BY ETHANOL-WATER SYSTEM IN HUMAN SKIN. PHARMACEUTICAL RESEARCH, 7, 762. HTTP://DX.DOI.ORG/10.1023/A:1015879925147</mixed-citation></ref><ref id="scirp.45843-ref14"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>KRISHNAIAH</surname><given-names> Y.S.R.</given-names></name>,<name name-style="western"><surname> SATYANAVAYANA</surname><given-names> V. </given-names></name>,<name name-style="western"><surname> KARTHIKEYAN</surname><given-names> R.S. </given-names></name>,<etal>et al</etal>. (2002)<article-title>KRISHNAIAH, Y.S.R., SATYANAVAYANA, V. AND KARTHIKEYAN, R.S.  EFFECT OF SOLVENT SYSTEM ON THE IN-VITRO PERMEABILITY OF NICARDIPINE HYDROCHLORIDE THROUGH EXCISED RAT EPIDERMIS</article-title><source>. JOURNAL OF PHARMACY &amp; PHARMACEUTICAL SCIENCES</source><volume> 5</volume>,<fpage> 123</fpage>-<lpage>130</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.45843-ref15"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>TOUITOU</surname><given-names> E.</given-names></name>,<name name-style="western"><surname> DYAN</surname><given-names> N.</given-names></name>,<name name-style="western"><surname> BERGELSON</surname><given-names> L.</given-names></name>,<name name-style="western"><surname> SODIN</surname><given-names> B. </given-names></name>,<name name-style="western"><surname> ELIAZ</surname><given-names> M. </given-names></name>,<etal>et al</etal>. (<year>2000</year>)<article-title>ETHOSOMES NOVEL VESICULAR CARRIERS FOR ENHANCED DELIVERY: CHARACTERIZATION AND SKIN PENETRATION PROPERTIES</article-title><source>. JOURNAL OF CONTROLLED RELEASE</source><volume> 65</volume>,<fpage> 403</fpage>-<lpage>418</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/S0168-3659(99)00222-9</pub-id></mixed-citation></ref><ref id="scirp.45843-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">JAIN, S., TIWARY, A.K., SAPRA, B. AND JAIN, N.K. (2007) FORMULATION AND EVALUATION OF ETHOSOMES FOR TRANSDERMAL DELIVERY OF LAMIVUDINE. AAPS PHARMSCITECH: AN OFFICIAL JOURNAL OF AMERICAN ASSOCIATION PF PHARMACEUTICAL SCIENTISTS, 8, E111.</mixed-citation></ref><ref id="scirp.45843-ref17"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>TONITON</surname><given-names> E. </given-names></name>,<etal>et al</etal>. (<year>1986</year>)<article-title>TRANSDERMAL DELIVERY OF ANXIOLYTICS: IN VITRO SKIN PERMEATION OF MIDAZOLAM MALEATE AND DIAZEPAM</article-title><source>. INTERNATIONAL JOURNAL OF PHARMACEUTICS</source><volume> 33</volume>,<fpage> 37</fpage>-<lpage>43</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/0378-5173(86)90036-0</pub-id></mixed-citation></ref><ref id="scirp.45843-ref18"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>OBATA</surname><given-names> Y.</given-names></name>,<name name-style="western"><surname> TAGAYAMAK</surname><given-names> K.</given-names></name>,<name name-style="western"><surname> MAITAN</surname><given-names> Y.</given-names></name>,<name name-style="western"><surname> MACHIDE</surname><given-names> Y. </given-names></name>,<name name-style="western"><surname> NAGA</surname><given-names> T. </given-names></name>,<etal>et al</etal>. (<year>1993</year>)<article-title>EFFECT OF ETHANOL ON SKIN PERMEATION OF NONIONIZED AND IONIZED DICLOFENAC</article-title><source>. INTERNATIONAL JOURNAL OF PHARMACEUTICS</source><volume> 89</volume>,<fpage> 191</fpage>-<lpage>198</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/0378-5173(93)90243-9</pub-id></mixed-citation></ref><ref id="scirp.45843-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">LAGROW, B. (2005) PHYSICIANS’ DESK REFERENCE. 59TH EDITION, THOMSON PDR, NEW JERSEY, 2590.</mixed-citation></ref><ref id="scirp.45843-ref20"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>BOONME</surname><given-names> P.</given-names></name>,<name name-style="western"><surname> KRAUEL</surname><given-names> K.</given-names></name>,<name name-style="western"><surname> GRAF</surname><given-names> A.</given-names></name>,<name name-style="western"><surname> RADES</surname><given-names> T. </given-names></name>,<name name-style="western"><surname> JUNYAPRASERT</surname><given-names> V.B. </given-names></name>,<etal>et al</etal>. (2006)<article-title>BOONME, P., KRAUEL, K., GRAF, A., RADES, T. AND JUNYAPRASERT, V.B.  CHARACTERIZATION OF MICROEMULSION STRUCTURE IN THE PSEUDOTERNARY PHASE DIAGRAM OF ISOPROPYL PALMITATE/WATER/BRIJ 97:1-BUTANOL</article-title><source>. AAPS PHARMSCITECH: AN OFFICIAL JOURNAL OF AMERICAN ASSOCIATION PF PHARMACEUTICAL SCIENTISTS</source><volume> 7</volume>,<fpage> E99</fpage>-<lpage>E104</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.45843-ref21"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>MBAH</surname><given-names> C.J. </given-names></name>,<name name-style="western"><surname> NNADI</surname><given-names> C.O. </given-names></name>,<etal>et al</etal>. (<year>2010</year>)<article-title>THE IN VITRO PERMEABILITY OF VALSARTAN THROUGH EXCISED RAT SKIN</article-title><source>. BIO-RESEARCH</source><volume> 8</volume>,<fpage> 598</fpage>-<lpage>601</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.4314/BR.V8I1.62540</pub-id></mixed-citation></ref><ref id="scirp.45843-ref22"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SONGKRO</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> PURWO</surname><given-names> Y.</given-names></name>,<name name-style="western"><surname> BECKET</surname><given-names> G. </given-names></name>,<name name-style="western"><surname> RADES</surname><given-names> T. </given-names></name>,<etal>et al</etal>. (2003)<article-title>SONGKRO, S., PURWO, Y., BECKET, G. AND RADES, T.  INVESTIGATION OF NEWBORN PIG SKIN AS AN IN VITRO ANIMAL MODEL FOR TRANSDERMAL DRUG DELIVERY</article-title><source>. STP PHARMA SCIENCES</source><volume> 13</volume>,<fpage> 133</fpage>-<lpage>139</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.45843-ref23"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>BHATIA</surname><given-names> K.S.</given-names></name>,<name name-style="western"><surname> GAO</surname><given-names> S. </given-names></name>,<name name-style="western"><surname> SINGH</surname><given-names> J. </given-names></name>,<etal>et al</etal>. (<year>1997</year>)<article-title>EFFECTS OF PENETRATION ENHANCERS AND IONTOPHORESIS ON FTIR SPECTROSCOPY AND LHRH PERMEABILITY THROUGH PORCINE SKIN</article-title><source>. JOURNAL OF CONTROLLED RELEASE</source><volume> 47</volume>,<fpage> 81</fpage>-<lpage>89</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/S0168-3659(96)01618-5</pub-id></mixed-citation></ref><ref id="scirp.45843-ref24"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>WALKER</surname><given-names> R.B. </given-names></name>,<name name-style="western"><surname> SMITH</surname><given-names> E.W. </given-names></name>,<etal>et al</etal>. (<year>1996</year>)<article-title>THE ROLE OF PERCUTANEOUS PENETRATION ENHANCERS</article-title><source>. ADVANCED DRUG DELIVERY REVIEWS</source><volume> 18</volume>,<fpage> 295</fpage>-<lpage>301</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/0169-409X(95)00078-L</pub-id></mixed-citation></ref><ref id="scirp.45843-ref25"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>PAUL</surname><given-names> B.K. </given-names></name>,<name name-style="western"><surname> MONLIK</surname><given-names> S.P. </given-names></name>,<etal>et al</etal>. (<year>1997</year>)<article-title>MICROEMULSIONS: AN OVERVIEW</article-title><source>. JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY</source><volume> 18</volume>,<fpage> 301</fpage>-<lpage>367</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1080/01932699708943740</pub-id></mixed-citation></ref><ref id="scirp.45843-ref26"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>LAWRENCE</surname><given-names> M.J. </given-names></name>,<name name-style="western"><surname> REES</surname><given-names> G.D. </given-names></name>,<etal>et al</etal>. (<year>2000</year>)<article-title>MICROEMULSION-BASED MEDIA AS NOVEL DRUG DELIVERY SYSTEMS</article-title><source>. ADVANCED DRUG DELIVERY REVIEWS</source><volume> 45</volume>,<fpage> 89</fpage>-<lpage>121</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/S0169-409X(00)00103-4</pub-id></mixed-citation></ref><ref id="scirp.45843-ref27"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>GOLDEN</surname><given-names> G.M.</given-names></name>,<name name-style="western"><surname> GUZEK</surname><given-names> D.B.</given-names></name>,<name name-style="western"><surname> HARRIS</surname><given-names> R.R.</given-names></name>,<name name-style="western"><surname> MEKIE</surname><given-names> J.E. </given-names></name>,<name name-style="western"><surname> POUS</surname><given-names> R.D. </given-names></name>,<etal>et al</etal>. (<year>1986</year>)<article-title>LIPID THERMOTROPIC TRANSITION IN HUMAN STRATUM CORNEUM</article-title><source>. JOURNAL OF INVESTIGATIVE DERMATOLOGY</source><volume> 86</volume>,<fpage> 255</fpage>-<lpage>259</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1111/1523-1747.EP12285373</pub-id></mixed-citation></ref><ref id="scirp.45843-ref28"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SOATES</surname><given-names> C.Y. </given-names></name>,<name name-style="western"><surname> KNUTSON</surname><given-names> K. </given-names></name>,<etal>et al</etal>. (1994)<article-title>SOATES, C.Y. AND KNUTSON, K.  ENHANCED PERMEATION OF POLAR COMPOUNDS THROUGH HUMAN EPIDERMIS. PERMEABILITY AND MEMBRANE STRUCTURAL CHANGES IN THE PRESENCE OF SHORT CHAIN ALCOHOLS</article-title><source>. BIOCHIMICA ET BIOPHYSICA ACTA</source><volume> 1195</volume>,<fpage> 169</fpage>-<lpage>179</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.45843-ref29"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>BARRY</surname><given-names> B.W. </given-names></name>,<etal>et al</etal>. (<year>1991</year>)<article-title>LIPID-PROTEIN PARTITIONING OF SKIN PENETRATION ENHANCEMENT</article-title><source>. JOURNAL OF CONTROLLED RELEASE</source><volume> 15</volume>,<fpage> 237</fpage>-<lpage>248</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/0168-3659(91)90115-T</pub-id></mixed-citation></ref><ref id="scirp.45843-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">ROBERTS, M.S. AND WALKER, M. (1993) PENETRATION ENHANCEMENT BY STRATUM CORNEUM MODIFICATION. IN: PHARMACEUTICAL SKIN PENETRATION ENHANCEMENT, MARCEL DEKKER, NEW YORK, 1-30.</mixed-citation></ref><ref id="scirp.45843-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">WESTER, R.C. AND MAIBACH, H.I. (1995) EFFECT OF OILY VEHICLES ON SKIN HYDRATION AND PENETRATION RATE. IN: PERCUTANEOUS PENETRATION ENHANCERS, CRC PRESS, BOCA RATON, 21-28.</mixed-citation></ref><ref id="scirp.45843-ref32"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>BENSON</surname><given-names> H.A.E. </given-names></name>,<etal>et al</etal>. (<year>2005</year>)<article-title>TRANSDERMAL DRUG DELIVERY: PENETRATION ENHANCEMENT TECHNIQUES</article-title><source>. CURRENT DRUG DELIVERY</source><volume> 2</volume>,<fpage> 23</fpage>-<lpage>33</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.2174/1567201052772915</pub-id></mixed-citation></ref></ref-list></back></article>